Home › Liver Cancer › NCT06261814
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
2D and 3D Contrast Enhanced Ultrasound of Chemoembolization
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Scheduled for TACE therapy of a liver tumor * Be at least 18 years of age * Be medically stable * If a female of child-bearing age, must have a negative pregnancy test * Have signed informed consent to participate in the study Exclusion Criteria: * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable * Patients with known sensitivities to the components of lumason
About the study
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.
What is being tested
- Sulfur Hexafluoride Lipid Microspheres (drug)
- Contrast-Enhanced Ultrasound (procedure)
- Transarterial Chemoembolization (procedure)
- Medical Chart Review (other)
Sponsor: john eisenbrey · Participants: 266 · Started: Aug 7, 2024
Contact the study team
- John Eisenbrey, PhD · Phone: 215-503-5188
Official record on ClinicalTrials.gov — NCT06261814
Locations in the U.S.
| Pennsylvania | Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.